We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Biogen Idec and Elan’s application to reintroduce the multiple sclerosis (MS) drug Tysabri (natalizumab) is a high priority, the FDA said in response to the firms’ announcement that the agency had extended its review period by 90 days.